Is Sarepta Therapeutics Inc halal to invest in?

As of July 2026, Sarepta Therapeutics Inc SRPT is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Sarepta Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sarepta Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Sarepta Therapeutics Inc?

Muslim investors may consider investing in Sarepta Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Sarepta Therapeutics Inc classified as HALAL?

Musaffa determines the Shariah status of Sarepta Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Sarepta Therapeutics Inc updated?

The Shariah compliance status of Sarepta Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Sarepta Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Sarepta Therapeutics Inc?

You can check the latest Shariah compliance status of Sarepta Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

SRPT Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Sarepta Therapeutics Inc is classified as halal.

HALAL

Report Source: 2026 1st Quarter Report

Sarepta Therapeutics Inc. Stock Analysis SRPT

United States Health Care Mid Cap Report: Q1, 2026

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 835 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.

Key Statistics of Sarepta Therapeutics Inc (SRPT)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$16.83$17.70

Today's Open

$17.39

Volume

1.78M

P/E Ratio (TTM)

52 Week Range

$10.42$25.32

Market Cap

2.13B

Avg. Volume

4.21M

Dividend Yield

Financial Metrics & Statements of Sarepta Therapeutics Inc (SRPT)

Super Investors Invested in Sarepta Therapeutics Inc (SRPT)

FAQ's for Sarepta Therapeutics Inc (SRPT)

As of July 2026, Sarepta Therapeutics Inc SRPT is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sarepta Therapeutics Inc using these criteria to determine its compliance status.
Muslim investors may consider investing in Sarepta Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Sarepta Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Sarepta Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Sarepta Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.